Skip to content

Surgery With or Without Lymph Node Removal in Treating Older Women With Stage I Breast Cancer

QUADRANTECTOMY PLUS AXILLARY DISSECTION VERSUS QUADRANTECTOMY ALONE IN MAMMOGRAPHIC STAGE T1N0 BREAST CANCER PATIENTS AGED OVER 65 YEARS

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00002720
Enrollment
642
Registered
2003-01-27
Start date
1995-12-31
Completion date
2012-12-31
Last updated
2013-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

stage I breast cancer

Brief summary

RATIONALE: Surgery to remove axillary lymph nodes may be an effective treatment for women with breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of therapy with or without axillary lymph node dissection following quadrantectomy in treating older women with stage I breast cancer that is estrogen receptor positive.

Detailed description

OBJECTIVES: * Compare the efficacy of quadrantectomy with or without axillary lymph node dissection, followed by tamoxifen in terms of local and distant relapse rates and overall survival of patients with stage I, invasive breast cancer. * Determine the relationship between biological variables, such as hormone receptor status, cell proliferation, and DNA ploidy, and the clinical outcome of the disease in these patients. OUTLINE: This is a randomized, multicenter study. Patients are stratified by center. Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients undergo quadrantectomy with dissection of level I and II axillary lymph nodes. * Arm II: Patients undergo quadrantectomy without axillary lymph node dissection. Patients on both arms receive tamoxifen daily for 5 years. Patients are followed every 4 months for 2 years, every 6 months for 2 years, and then annually thereafter. PROJECTED ACCRUAL: A total of 642 patients will be accrued for this study within 3 years.

Interventions

DRUGtamoxifen citrate
PROCEDUREconventional surgery

Sponsors

European Institute of Oncology
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Primary purpose
TREATMENT

Eligibility

Sex/Gender
FEMALE
Age
65 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

DISEASE CHARACTERISTICS: * Histologically proven stage I, invasive breast cancer * Hormone receptor status: * Estrogen receptor positive * Progesterone receptor positive or negative PATIENT CHARACTERISTICS: Age: * 65 to 80 Sex: * Female Menopausal status: * Postmenopausal Performance status: * Not specified Life Expectancy: * Not specified Hematopoietic: * Not specified Hepatic: * Not specified Renal: * Not specified Other: * No serious disease that would preclude surgery * No other prior or concurrent malignancy except basal cell carcinoma or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: * Not specified

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 24, 2026